18 May 2020 07:00
REDX PHARMA PLC
("Redx" or "the Company")
聽
Appointment of Non-Executive Director with Deep Experience of the Biotechnology Industry and Capital Markets
聽
Alderley Park, 18 May 2020 Redx Pharma (AIM:REDX), the drug discovery and development company focused on cancer and fibrosis, is pleased to announce the appointment of Sarah Gordon Wild as an Independent non-Executive Director, with effect from 1 July 2020. Sarah brings extensive investment experience in the biotechnology sector to her role at Redx. She currently also serves as a Non-Executive Director of Oxford Nanopore Technologies and Evox Therapeutics, as well as being a Board Member of Lone Pine Capital LLC's Offshore Funds.
聽
Between 1998-2003 Sarah was Managing Director, Management Committee Member and Senior Healthcare Analyst at Lone Pine Capital LLC. Before this, for over 15 years, Sarah was a senior biotechnology/healthcare analyst on Wall Street at firms including; Amerindo Investments Advisors, Hambrecht & Quist, Kleinwort Grieveson, and Greig Middleton. She graduated from Aberdeen University with a BSc (Hons) in Zoology and with an MSc from Imperial College, London in Social & Economic Aspects of Science and Technology in Industry.
聽
Iain Ross, Chairman of the Board of Redx commented: "We are delighted to welcome Sarah to the Board. I am confident that Redx will benefit from her counsel and deep understanding of the biotechnology sector and capital markets as we seek to build a leading biotech company focused on novel medicines that have the potential to transform the treatment of oncology and fibrosis."
聽
Sarah Gordon Wild commented: "I am excited to be joining the Board as a non-executive director. Over a relatively short space of time, Redx has established a strong track record as a medicinal chemistry team and now has focused on a few very exciting programmes, as well as a strong management team. I look forward to seeing this pipeline progress in my Board role."聽
聽
Additional information:
聽
The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies:
聽
Sarah Gordon Wild, aged 61, is currently a director of:
聽
路 Oxford Nanopore Technologies Limited
路 Evox Therapeutics Limited
路 SGW Research Limited
路 Larkham Limited
路 The Bridport Literary Festival Limited
路 Leweston School Trust
聽
She is a partner in Dukes Auctioneers (Dorchester)
聽
She is also a member of the Lone Pine Capital Offshore Board
聽
She does not currently hold any ordinary shares in the Company.
聽
For further information, please contact:
聽
Redx Pharma Plc聽 | T: +44 1625 469 918 |
Iain Ross, Chairman Lisa Anson, Chief Executive | |
Cantor Fitzgerald Europe (Nominated Advisor & Joint Broker) | 聽T: +44 20 7894 7000 |
Phil Davies | |
WG Partners LLP (Joint Broker) | T: +44 20 3705 9330 |
Claes Sp氓ng/ Chris Lee/ David Wilson | |
FTI Consulting | T: +44 20 3727 1000 |
Simon Conway/Ciara Martin |
聽
About Redx Pharma Plc
聽
Redx is a UK based biotechnology company whose shares are traded on AIM (AIM:REDX). Redx's vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.
聽
If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts/
聽
聽